PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Real-World Foslevodopa/Foscarbidopa: OFF Time Falls 2.8 Hours, With 27.6% Early Discontinuation

foslevodopafoscarbidopalevodopacontinuous subcutaneous infusionadvanced Parkinson's diseasemotor fluctuationsOFF timedyskinesiareal-world evidencedevice-aided therapyobservational studyinfusion site reactionshallucinations Neurology / Neuropharmacology

Background Information

Six-month interim data shows promise for 24-hour Parkinson's infusion.

Continuous subcutaneous infusion could offer improved management of motor fluctuations in advanced Parkinson's disease. A significant reduction in OFF time by 2.8 hours and improvements in quality of life metrics over six months. While promising, the study is an interim analysis with a limited patient cohort and requires further results for comprehensive conclusions. Foslevodopa/foscarbidopa reduces OFF time and enhances quality of life in advanced Parkinson's patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jost WH, Bergquist F, Evans A, Hassin-Baer S, Hauser RA, Henriksen T, Malaty IA, Mestre TA, Mir P, Rodriguez R, Schwingenschuh P, Simu M, Bergmann L, Zhou TT, Caughlin S, Gopalkrishnan M, Kukreja P, O'Meara M, Parra JC, Shah MB, Aldred J

Citation: Jost WH, Bergquist F, Evans A, et al. Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results. Neurology and therapy. 2026;15(4):1743-1762. doi:10.1007/s40120-026-00948-6

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.